Eli Lilly (LLY) rallied 5% after the FDA approved orforglipron for chronic weight management. The drug is approved for use with a reduced-calorie diet and increased physical activity in adults with obesity or overweight with comorbidities. The approval was granted 294 days early via the FDA's priority voucher pilot program.